|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Lansoprazole results in increased expression of ABCA1 protein Lansoprazole results in increased expression of ABCA1 mRNA; Lansoprazole results in increased expression of ABCA1 protein |
CTD |
PMID:20060385 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1 affects the susceptibility to Lansoprazole |
CTD |
PMID:19238367 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
ISO |
Lansoprazole results in increased expression of APOE mRNA; Lansoprazole results in increased expression of APOE protein |
CTD |
PMID:20060385 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Aqp4 |
aquaporin 4 |
increases expression |
ISO |
Lansoprazole results in increased expression of AQP4 mRNA; Lansoprazole results in increased expression of AQP4 protein |
CTD |
PMID:20437101 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in decreased expression of BCL2 mRNA] |
CTD |
PMID:28412091 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C1QA mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C1QC mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C4BPA mRNA |
CTD |
PMID:25626140 |
|
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
|
|
G |
C4bpb |
complement component 4 binding protein, beta |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C4BPB mRNA |
CTD |
PMID:25626140 |
|
NCBI chr13:42,120,798...42,131,515
Ensembl chr13:42,120,798...42,131,817
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Lansoprazole inhibits the reaction [Demecolcine results in increased activity of CASP3 protein] Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of CASP3 mRNA]; Lansoprazole inhibits the reaction [Ethanol results in increased expression of CASP3 protein] |
CTD |
PMID:12530016 PMID:28412091 PMID:29339218 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:18726076 PMID:29339218 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cfi |
complement factor I |
decreases expression |
EXP |
Lansoprazole results in decreased expression of CFI mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 2:218,389,079...218,430,565
Ensembl chr 2:218,387,990...218,430,561
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression multiple interactions |
EXP |
Lansoprazole results in decreased expression of CXCL1 mRNA; Lansoprazole results in decreased expression of CXCL1 protein Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]; Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein] |
CTD |
PMID:15334676 PMID:16328016 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression decreases activity |
ISO EXP |
Lansoprazole results in increased activity of CYP1A1 promoter Lansoprazole results in increased expression of CYP1A1 mRNA; Lansoprazole results in increased expression of CYP1A1 protein Lansoprazole results in decreased activity of CYP1A1 protein |
CTD |
PMID:8169844 PMID:8647108 PMID:8900397 PMID:9041675 PMID:9152597 PMID:9860486 PMID:10859152 PMID:12623754 PMID:14550749 PMID:18502397 PMID:25626140 PMID:33814510 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO EXP |
Lansoprazole results in increased expression of CYP1A2 mRNA; Lansoprazole results in increased expression of CYP1A2 protein |
CTD |
PMID:8169844 PMID:9152597 PMID:9744552 PMID:12623754 PMID:14550749 PMID:25626140 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression decreases activity |
ISO |
Lansoprazole results in increased expression of CYP1B1 mRNA Lansoprazole results in decreased activity of CYP1B1 protein |
CTD |
PMID:12623754 PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP2B1 protein |
CTD |
PMID:9152597 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP2B2 protein |
CTD |
PMID:9152597 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases hydroxylation multiple interactions |
ISO |
CYP2C9 protein results in increased hydroxylation of Lansoprazole Lansoprazole inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Diclofenac] CYP2C18 protein results in increased hydroxylation of Lansoprazole |
CTD |
PMID:7870052 PMID:8627562 PMID:12975331 PMID:15258107 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects response to substance multiple interactions decreases metabolic processing increases metabolic processing affects metabolic processing increases hydroxylation decreases activity increases expression |
ISO EXP |
CYP2C19 gene affects the susceptibility to Lansoprazole; CYP2C19 gene polymorphism affects the susceptibility to Lansoprazole CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]; Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] CYP2C19 gene polymorphism results in decreased metabolism of Lansoprazole CYP2C19 protein results in increased metabolism of Lansoprazole; Lansoprazole results in increased metabolism of CYP2C19 protein CYP2C19 protein affects the metabolism of Lansoprazole CYP2C19 protein results in increased hydroxylation of Lansoprazole Lansoprazole results in decreased activity of CYP2C19 protein Lansoprazole results in increased expression of CYP2C6V1 mRNA; Lansoprazole results in increased expression of CYP2C6V1 protein |
CTD |
PMID:8627562 PMID:8930576 PMID:9152597 PMID:9272410 PMID:11829200 PMID:11929404 PMID:12975331 PMID:14550749 PMID:15010519 PMID:15258107 PMID:15285851 PMID:15963082 PMID:17377957 PMID:19814645 PMID:21212520 PMID:21795468 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects metabolic processing increases hydroxylation |
ISO |
CYP2C8 protein affects the metabolism of Lansoprazole CYP2C8 protein results in increased hydroxylation of Lansoprazole |
CTD |
PMID:7870052 PMID:8627562 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases degradation multiple interactions |
ISO |
Lansoprazole results in decreased degradation of CYP2E1 protein Lansoprazole results in increased expression of and results in increased activity of CYP2E1 protein |
CTD |
PMID:36243147 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing affects metabolic processing increases expression increases hydroxylation |
ISO |
CYP3A4 protein results in increased metabolism of Lansoprazole CYP3A4 protein affects the metabolism of Lansoprazole Lansoprazole results in increased expression of CYP3A4 mRNA; Lansoprazole results in increased expression of CYP3A4 protein CYP3A4 protein results in increased hydroxylation of Lansoprazole |
CTD |
PMID:7870052 PMID:8627562 PMID:8930576 PMID:9744552 PMID:10859152 PMID:11829200 PMID:12975331 PMID:15010519 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] |
CTD |
PMID:17377957 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP4A1 protein |
CTD |
PMID:9152597 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
Lansoprazole results in increased expression of EGFR protein |
CTD |
PMID:9881512 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FAS protein] |
CTD |
PMID:29339218 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FASLG protein] |
CTD |
PMID:29339218 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
ISO |
Lansoprazole results in decreased expression of FGF2 protein |
CTD |
PMID:9881512 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
Lansoprazole results in increased expression of FGF21 protein |
CTD |
PMID:8774986 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Gast |
gastrin |
increases expression |
ISO EXP |
Lansoprazole results in increased expression of GAST protein |
CTD |
PMID:7750667 PMID:8792694 PMID:11680587 PMID:11975934 PMID:12189558 PMID:12438555 PMID:20095383 More...
|
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Lansoprazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
ISO |
Lansoprazole results in increased expression of HAMP mRNA |
CTD |
PMID:31669099 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; Lansoprazole results in increased activity of and results in increased expression of HMOX1 protein Lansoprazole results in increased activity of HMOX1 promoter 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased activity of HMOX1 promoter] Lansoprazole results in increased expression of HMOX1 protein Lansoprazole results in increased expression of HMOX1 mRNA; Lansoprazole results in increased expression of HMOX1 protein Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Lansoprazole results in increased expression of HMOX1 protein] |
CTD |
PMID:16712795 PMID:19628634 PMID:19764090 PMID:28412091 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
ISO |
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 PMID:19232345 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein] |
CTD |
PMID:29339218 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Lansoprazole results in decreased expression of IL1B mRNA Lansoprazole inhibits the reaction [Ethanol results in increased expression of IL1B protein] |
CTD |
PMID:16932910 PMID:29339218 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO EXP |
Lansoprazole results in decreased expression of IL6 mRNA Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 mRNA] |
CTD |
PMID:16932910 PMID:28412091 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases oxidation |
EXP |
Lansoprazole results in increased oxidation of KEAP1 protein |
CTD |
PMID:19628634 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions increases expression |
EXP |
Lansoprazole inhibits the reaction [LHB protein results in increased abundance of Testosterone] Lansoprazole results in increased expression of LHB protein |
CTD |
PMID:7589908 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
EXP |
Lansoprazole results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19628634 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
EXP |
Lansoprazole results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19628634 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
affects binding |
ISO |
Lansoprazole binds to MAPT protein alternative form |
CTD |
PMID:20110603 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:17151854 PMID:17895592 PMID:18726076 PMID:24337826 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases phosphorylation increases expression |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of NFE2L2 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein] Lansoprazole results in increased phosphorylation of NFE2L2 protein Lansoprazole results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19628634 PMID:28412091 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29339218 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1H2 protein |
CTD |
PMID:20060385 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1H3 protein |
CTD |
PMID:20060385 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
decreases activity |
ISO |
Lansoprazole results in decreased activity of PHOSPHO1 protein |
CTD |
PMID:17227223 |
|
NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
ISO |
Lansoprazole results in increased expression of POMC protein |
CTD |
PMID:16524691 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
AG-041R inhibits the reaction [Lansoprazole results in increased expression of PTGS2 protein] |
CTD |
PMID:12438555 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:29339218 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retsat |
retinol saturase |
decreases expression |
EXP |
Lansoprazole results in decreased expression of RETSAT mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Serping1 |
serpin family G member 1 |
decreases expression |
EXP |
Lansoprazole results in decreased expression of SERPING1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034
|
|
G |
Shh |
sonic hedgehog signaling molecule |
decreases expression |
ISO |
Lansoprazole results in decreased expression of SHH mRNA |
CTD |
PMID:20437101 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Lansoprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions |
ISO |
[Lansoprazole results in decreased activity of SLC22A8 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Lansoprazole results in increased expression of TGFA protein |
CTD |
PMID:9881512 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Lansoprazole results in increased expression of TGFB1 protein |
CTD |
PMID:36243147 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole results in decreased expression of TNF mRNA Lansoprazole inhibits the reaction [Ethanol results in increased expression of TNF protein] |
CTD |
PMID:16932910 PMID:19232345 PMID:29339218 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA] |
CTD |
PMID:28412091 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
Lansoprazole results in increased expression of UGT1A1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
increases expression |
EXP |
Lansoprazole results in increased expression of UGT2B1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|